Beta-2-microglobulin as a tumor marker in solid malignancies

Milvia Lotzniker, Franco Pavesi, Laura Marbello, Remigio Moratti

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Beta-2-microglobulin (β2-MG) and CF.A were measured in the sera of 186 cancer patients divided into two groups: At diagnosis (D) and at follow-up (F). Four groups of patients at diagnosis (D-I, D-II, D-III and D-IV according to TNM classification) and two at follow-up (in remission. F-R S, and in relapse. F-R P) were considered. All patients had normal serum creatinine and urea concentrations. β2-MG values in D-l were significantly (p 100 ng/ml revealed β2-MG values close to those of groups D-I and D-IV. In 10% of patients in stage IV or with CEA > 100 ng/ml β2-MG was lower than the mean value of the healthy population. From data β2-MG is probably produced by an aspecific reaction to the tumor and the decrease in advanced stages could express a decreased immunologic response. On the other hand, high serum β2-MG in the initial stages of the neoplasia may reflect an elevated cell turnover, while low β2-MG during the final stages may be due to a weak expression of the protein by highly undifferentiated cells.

Original languageEnglish
Pages (from-to)162-165
Number of pages4
JournalOncology
Volume45
Issue number3
DOIs
Publication statusPublished - 1988

Fingerprint

beta 2-Microglobulin
Tumor Biomarkers
Neoplasms
Serum
Neoplasm Staging
Urea
Creatinine
Recurrence
Population
Proteins

Keywords

  • Carcinoembryonic antigen
  • Solid tumors
  • Tumor marker
  • β<inf>2</inf>-Microglobulin

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Lotzniker, M., Pavesi, F., Marbello, L., & Moratti, R. (1988). Beta-2-microglobulin as a tumor marker in solid malignancies. Oncology, 45(3), 162-165. https://doi.org/10.1159/000226555

Beta-2-microglobulin as a tumor marker in solid malignancies. / Lotzniker, Milvia; Pavesi, Franco; Marbello, Laura; Moratti, Remigio.

In: Oncology, Vol. 45, No. 3, 1988, p. 162-165.

Research output: Contribution to journalArticle

Lotzniker, M, Pavesi, F, Marbello, L & Moratti, R 1988, 'Beta-2-microglobulin as a tumor marker in solid malignancies', Oncology, vol. 45, no. 3, pp. 162-165. https://doi.org/10.1159/000226555
Lotzniker M, Pavesi F, Marbello L, Moratti R. Beta-2-microglobulin as a tumor marker in solid malignancies. Oncology. 1988;45(3):162-165. https://doi.org/10.1159/000226555
Lotzniker, Milvia ; Pavesi, Franco ; Marbello, Laura ; Moratti, Remigio. / Beta-2-microglobulin as a tumor marker in solid malignancies. In: Oncology. 1988 ; Vol. 45, No. 3. pp. 162-165.
@article{1f94815f897646f7afd0a97094881b9b,
title = "Beta-2-microglobulin as a tumor marker in solid malignancies",
abstract = "Beta-2-microglobulin (β2-MG) and CF.A were measured in the sera of 186 cancer patients divided into two groups: At diagnosis (D) and at follow-up (F). Four groups of patients at diagnosis (D-I, D-II, D-III and D-IV according to TNM classification) and two at follow-up (in remission. F-R S, and in relapse. F-R P) were considered. All patients had normal serum creatinine and urea concentrations. β2-MG values in D-l were significantly (p 100 ng/ml revealed β2-MG values close to those of groups D-I and D-IV. In 10{\%} of patients in stage IV or with CEA > 100 ng/ml β2-MG was lower than the mean value of the healthy population. From data β2-MG is probably produced by an aspecific reaction to the tumor and the decrease in advanced stages could express a decreased immunologic response. On the other hand, high serum β2-MG in the initial stages of the neoplasia may reflect an elevated cell turnover, while low β2-MG during the final stages may be due to a weak expression of the protein by highly undifferentiated cells.",
keywords = "Carcinoembryonic antigen, Solid tumors, Tumor marker, β<inf>2</inf>-Microglobulin",
author = "Milvia Lotzniker and Franco Pavesi and Laura Marbello and Remigio Moratti",
year = "1988",
doi = "10.1159/000226555",
language = "English",
volume = "45",
pages = "162--165",
journal = "Oncology",
issn = "0030-2414",
publisher = "UBM Medica Healthcare Publications",
number = "3",

}

TY - JOUR

T1 - Beta-2-microglobulin as a tumor marker in solid malignancies

AU - Lotzniker, Milvia

AU - Pavesi, Franco

AU - Marbello, Laura

AU - Moratti, Remigio

PY - 1988

Y1 - 1988

N2 - Beta-2-microglobulin (β2-MG) and CF.A were measured in the sera of 186 cancer patients divided into two groups: At diagnosis (D) and at follow-up (F). Four groups of patients at diagnosis (D-I, D-II, D-III and D-IV according to TNM classification) and two at follow-up (in remission. F-R S, and in relapse. F-R P) were considered. All patients had normal serum creatinine and urea concentrations. β2-MG values in D-l were significantly (p 100 ng/ml revealed β2-MG values close to those of groups D-I and D-IV. In 10% of patients in stage IV or with CEA > 100 ng/ml β2-MG was lower than the mean value of the healthy population. From data β2-MG is probably produced by an aspecific reaction to the tumor and the decrease in advanced stages could express a decreased immunologic response. On the other hand, high serum β2-MG in the initial stages of the neoplasia may reflect an elevated cell turnover, while low β2-MG during the final stages may be due to a weak expression of the protein by highly undifferentiated cells.

AB - Beta-2-microglobulin (β2-MG) and CF.A were measured in the sera of 186 cancer patients divided into two groups: At diagnosis (D) and at follow-up (F). Four groups of patients at diagnosis (D-I, D-II, D-III and D-IV according to TNM classification) and two at follow-up (in remission. F-R S, and in relapse. F-R P) were considered. All patients had normal serum creatinine and urea concentrations. β2-MG values in D-l were significantly (p 100 ng/ml revealed β2-MG values close to those of groups D-I and D-IV. In 10% of patients in stage IV or with CEA > 100 ng/ml β2-MG was lower than the mean value of the healthy population. From data β2-MG is probably produced by an aspecific reaction to the tumor and the decrease in advanced stages could express a decreased immunologic response. On the other hand, high serum β2-MG in the initial stages of the neoplasia may reflect an elevated cell turnover, while low β2-MG during the final stages may be due to a weak expression of the protein by highly undifferentiated cells.

KW - Carcinoembryonic antigen

KW - Solid tumors

KW - Tumor marker

KW - β<inf>2</inf>-Microglobulin

UR - http://www.scopus.com/inward/record.url?scp=0023925331&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023925331&partnerID=8YFLogxK

U2 - 10.1159/000226555

DO - 10.1159/000226555

M3 - Article

C2 - 3285279

AN - SCOPUS:0023925331

VL - 45

SP - 162

EP - 165

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 3

ER -